½ÃÀ庸°í¼­
»óǰÄÚµå
1561071

¼¼°èÀÇ ¾ÐŸ¸Ó ½ÃÀå - ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : À¯Çüº°, ¿ëµµº°, Áö¿ªº° »ê¾÷ ¿¹Ãø(2024-2031³â)

Aptamers Market Size, Share, Growth Analysis, By Type(Nucleic Acid and Peptide), By Application(Diagnostics, Therapeutics, Research & Development, Others), By Region - Industry Forecast 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 219 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¾ÐŸ¸Ó ½ÃÀå ±Ô¸ð´Â 2022³â¿¡ 1¾ï 5,500¸¸ ´Þ·¯·Î, 2023³â 1¾ï 8,259¸¸ ´Þ·¯¿¡¼­ 2031³â±îÁö´Â 6¾ï 7,708¸¸ ´Þ·¯·Î ¼ºÀåÇØ ¿¹Ãø ±â°£(2024-2031³â)ÀÇ CAGRÀº 17.80%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¾ÐŸ¸Ó´Â »ý»ê, Á¤Á¦, Ç¥Àû ¾à¹° Àü´Þ¿¡ ´ëÇÑ ÃÖ±ÙÀÇ Áøº¸¿¡ À־ ¸íÈ®ÇÑ ÀåÁ¡À¸·Î ¿¬±¸ÀÚµé·ÎºÎÅÍ Å« °ü½ÉÀ» ²ø°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀåÁ¡Àº ÀüÅëÀûÀÎ Ç×ü¿¡ ºñÇØ ºÐÀÚ Å©±â°¡ ÀÛ°í, ¸é¿ª¿ø¼ºÀÌ ³·°í, Á¦Á¶ ºñ¿ëÀÌ Àý°¨µÇ°í, ºÎÀÛ¿ëÀÌ Àû´Ù´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Æ¯¼ºÀº Çõ½ÅÀûÀÎ ¾ÐŸ¸Ó °³¹ß¿¡ ±â¿©ÇÏ¸ç ½ÃÀå °³Ã´ÀÇ ¿øµ¿·ÂÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ±¤¹üÀ§ÇÑ Á¶»ç¿¡µµ ºÒ±¸Çϰí, ´Ù¾çÇÑ À¯ÀüÀû º¯ÀÌ·Î ÀÎÇÑ °¨¿°¿¡ ´ëÇÑ È¿°úÀûÀÎ Ä¡·á¹ýÀº ÇöÀç Á¸ÀçÇÏÁö ¾Ê½À´Ï´Ù. ±×·¯³ª SELEX ±â¼úÀ» ±â¹ÝÀ¸·Î ÇÑ Áø´Ü ŰƮ¿Í ºÐ¼®Àº °íÄ£ È­¼º ÁßÈ­Á¦ÀÇ »ý»ê¿¡ À¯¸ÁÇÏ´Ù´Â °ÍÀ» º¸¿©ÁÝ´Ï´Ù. ÀÌ ½ÃÀå °³Ã´Àº »õ·Î¿î Áø´Ü ŰƮ¸¦ äÅÃÇÏ¿© ½ÃÀå ¼ºÀåÀ» ±â´ëÇÕ´Ï´Ù. ¾ÐŸ¸Ó´Â DNA ¾ÐŸ¸Ó ±â¼úÀ» »ç¿ëÇÏ¿© °³¹ßµÈ 2¼¼´ë Áø´Ü µµ±¸ÀÔ´Ï´Ù. ÀÌ Å°Æ®´Â ºñ¿ë È¿À²ÀûÀ̰í È­ÇÐÀûÀ¸·Î ÇÕ¼ºµÇ¾î Áø´Ü¿¡¼­ Á¡Á¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 3¿ù, Soma LogicÀº SomaScan Assay¸¦ äÅÃÇÏ¿© European Prospective Investigation into Cancer and Nutrition(EPIC) ¿¬±¸¸¦ À§ÇØ 30,000°³ »ùÇÿ¡¼­ 2¾ï 1,000¸¸ °³ÀÇ ´Ü¹éÁú ÃøÁ¤Ä¡¸¦ ºÐ¼®ÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ƯÈ÷ ¾Ï°ú °°Àº Áúº´ ¿¹ÃøÀ» °­È­ÇÏ°í ½ÃÀå È®´ë¸¦ Áö¿øÇÏ´Â °ÍÀ» ¸ñÇ¥·ÎÇÕ´Ï´Ù. ¾ÐŸ¸Ó ±â¹Ý Áø´Ü ¼Ö·ç¼ÇÀº Å©±â°¡ ÀÛ°í, ƯÀ̼º, ¼±ÅüºÀÌ ³ô°í, ¼¼Æ÷ ¼öÁØÀÇ Áúº´ °ËÃâ¿¡ È¿°úÀûÀ̱⠶§¹®¿¡ Áø´Ü ½ÇÇè½Ç ¹× º´¸® ½ÇÇè½Ç¿¡ ÁöÁöµË´Ï´Ù. Cancer Research UK¿¡ µû¸£¸é 2040³â±îÁö ¾à 2,750¸¸¸íÀÌ ¾Ï Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖÀ¸¸ç, °í±Þ Áø´Ü ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

¼Ò°³

  • Á¶»çÀÇ ¸ñÀû
  • Á¤ÀÇ
  • ½ÃÀå ¹üÀ§

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷/1Â÷ Á¤º¸¿ø
  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀåÀÇ ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ

ÁÖ¿ä ¿ä¾à

  • ½ÃÀå °³¿ä Àü¸Á
  • °ø±Þ ¼ö¿ä µ¿Ç⠺м®
  • ºÎ¹®º° ±âȸ ºÐ¼®

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ±âȸ
    • ¾ïÁ¦¿äÀÎ
    • °úÁ¦
  • Porter's Five Forces ºÐ¼®

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • ÁÖ¿ä ¼º°ø ¿äÀÎ
  • °æÀïµµ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ½ÃÀå »ýŰè
  • ±â¼ú ºÐ¼®
  • ¹ë·ùüÀÎ ºÐ¼®
  • ƯÇ㠺м®

¾ÐŸ¸Ó ½ÃÀå : À¯Çüº°

  • ½ÃÀå °³¿ä
  • DNA ¾ÐŸ¸Ó
  • XNA ¾ÐŸ¸Ó
  • RNA ¾ÐŸ¸Ó

¾ÐŸ¸Ó ½ÃÀå : ±â¼úº°

  • ½ÃÀå °³¿ä
  • SELEX
  • ±âŸ ±â¼ú

¾ÐŸ¸Ó ½ÃÀå : ¿ëµµº°

  • ½ÃÀå °³¿ä
  • Ä¡·áÁ¦ °³¹ß
  • ¿¬±¸¡¤°³¹ß
  • Áø´Ü
  • ±âŸ ¿ëµµ

¾ÐŸ¸Ó ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ½ÃÀå °³¿ä
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Çмú¡¤Á¤ºÎ¿¬±¸±â°ü
  • ÀǾàǰ °³¹ß ¾÷¹« ¼öŹ ±â°ü
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

¾ÐŸ¸Ó ½ÃÀå ±Ô¸ð : Áö¿ªº°

  • ½ÃÀå °³¿ä
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(MEA)
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï ±¸µµ

  • »óÀ§ 5°³»ç ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2023³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤¿ëÇÑ Àü·«
  • ½ÃÀå¿¡¼­ÀÇ Ãֱ٠Ȱµ¿
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À²(2023³â)

ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Aptamer Group(UK)
  • Raptamer Discovery Group(US)
  • omalogic, Inc.(US)
  • Aptamer Sciences, Inc.(US)
  • Aptagen, LLC(US)
  • Maravai Lifesciences(US)
  • Kaneka Corporation(Japan)
  • Neoventures Biotechnology Inc.(Canada)
  • Aptus Biotech(Spain)
  • Base Pair Biotechnologies(US)
  • Amsbio(UK)
  • Novaptech(France)
  • Bio-Techne(US)
  • Aptitude Medical Systems(US)
  • Raybiotech, Inc.(US)
  • Alpha Diagnostic International, Inc.(US)
  • Creative Biolabs(US)
  • Creative Biogene(US)
  • Vivonics Inc.(US)
  • Iba Lifesciences GmbH(Germany)
  • Aptabharat Innovations Pvt. Ltd(India)
  • Profacgen(US)
  • Mediven(Germany)
  • Pure Biologics SA(Poland)
  • Oak Biosciences, Inc.(US)
JHS 24.10.04

Global Aptamers Market size was valued at USD 155 million in 2022 and is poised to grow from USD 182.59 million in 2023 to USD 677.08 million by 2031, growing at a CAGR of 17.80% during the forecast period (2024-2031).

Aptamers have gained significant interest from researchers due to their distinct advantages in recent advancements related to production, purification, and targeted drug delivery. These benefits include their small molecular size, low immunogenicity, reduced manufacturing costs, and fewer side effects compared to traditional antibodies. These attributes contribute to the potential development of innovative aptamers, which may drive market growth. Despite extensive research, there are currently no highly effective treatments for infections due to various genetic variations. However, SELEX technology-based diagnostic kits and assays have shown promise in generating high-affinity neutralizers. This development is expected to stimulate market growth with the introduction of new diagnostic kits. Aptamers represent a second-generation diagnostic tool developed using DNA aptamer technology. These kits are cost-effective, chemically synthesized, and increasingly popular in diagnostics. For instance, in March 2022, Soma Logic announced that it was employing the SomaScan Assay to analyze 210 million protein measurements from 30,000 samples for the European Prospective Investigation into Cancer and Nutrition (EPIC) study. This approach aims to enhance disease prediction, particularly cancer, thereby supporting market expansion. Aptamer-based diagnostic solutions are favored by diagnostic and pathology labs due to their small size, high specificity, selectivity, and effectiveness in cellular-level disease detection. According to Cancer Research UK, it is estimated that around 27.5 million people will receive a cancer diagnosis by 2040, underscoring the growing demand for advanced diagnostic technologies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Aptamers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Aptamers Market Segmental Analysis

Global Aptamers Market is segmented by Type, Technology, Application, End User, and region. Based on Type, the market is segmented into DNA Aptamers, XNA Aptamers, and RNA Aptamers. Based on Technology, the market is segmented into SELEX, Other Technologies. Based on Application, the market is segmented into Therapeutics Development, Research & Development, Diagnostics, Other Applications. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, Contract Research Organizations, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Aptamers Market

The increasing demand for personalized medicine is driving the growth of the global aptamers market. Aptamers, with their ability to bind specifically to target molecules such as proteins, peptides, and small compounds, are becoming essential in the development of targeted therapies and precision medicine. Their high specificity, low immunogenicity, and customizable nature make them ideal for personalized treatment strategies. Additionally, aptamers offer significant advantages over traditional antibodies, such as easier synthesis, cost-effective production, and enhanced binding affinity, making them highly attractive for diagnostic, therapeutic, and research applications.

Restraints in the Global Aptamers Market

Intellectual property (IP) issues pose significant challenges to the growth of the aptamers market. Patent rights and licensing agreements for aptamers and their associated technologies can restrict the commercialization potential for specific applications or targets. The complex IP landscape related to aptamer-based technologies can create legal uncertainties and obstacles for market participants. These IP complexities may impede market progress by making it difficult for companies to navigate patent claims and secure necessary licenses. Consequently, such legal barriers can limit the opportunities for innovation and expansion within the aptamers sector.

Market Trends of the Global Aptamers Market

SELEX (Systematic Evolution of Ligands by Exponential Enrichment) remains the leading technique for selecting aptamers. To boost efficiency, lower costs, and enhance the quality of aptamers, there is an increasing emphasis on optimizing and automating the SELEX process. Recent advancements in high-throughput screening, microfluidics, and robotics are being utilized to refine the aptamer development workflow, making it more efficient and scalable. These technological improvements aim to streamline the SELEX process, facilitating better and faster production of aptamers. By integrating these innovations, the process becomes more accessible and adaptable, addressing previous limitations and expanding the potential for aptamer applications.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factor
  • Degree of Competition
  • Top Investment Pockets
  • Ecosystem of the Market
  • Technology Analysis
  • Value Chain Analysis
  • Patent Analysis

Aptamers Market, By Type

  • Market Overview
  • DNA Aptamers
  • XNA Aptamers
  • RNA Aptamers

Aptamers Market, By Technology

  • Market Overview
  • SELEX
  • Other Technologies

Aptamers Market, By Application

  • Market Overview
  • Therapeutics Development
  • Research & Development
  • Diagnostics
  • Other Applications

Aptamers Market, By End User

  • Market Overview
  • Pharmaceutical & Biotechnology Companies
  • Academic & Government Research Institutes
  • Contract Research Organizations
  • Other End Users

Aptamers Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Aptamer Group (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Raptamer Discovery Group (US)
    • S Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • omalogic, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aptamer Sciences, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aptagen, LLC (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Maravai Lifesciences (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kaneka Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Neoventures Biotechnology Inc. (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aptus Biotech (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Base Pair Biotechnologies (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amsbio (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novaptech (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Techne (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aptitude Medical Systems (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Raybiotech, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alpha Diagnostic International, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Creative Biolabs (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Creative Biogene (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vivonics Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Iba Lifesciences GmbH (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aptabharat Innovations Pvt. Ltd (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Profacgen (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mediven (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pure Biologics SA (Poland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Oak Biosciences, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦